ArticleJournal of cachexia, sarcopenia and muscle2025
Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications.Frontiers in neurology · 2026Review
- Immunometabolic mechanisms of osteosarcopenic obesity: chronic inflammation, trained immunity, and systemic immune dysregulation.Frontiers in immunology · 2026Review
- Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAdalimumab, a TNF-α inhibitor, is widely used clinically. Recent studies suggest Adalimumab can improve muscle damage after ischemic stroke (IS), but its protective mechanisms remain unclear. This study investigates the effect of adalimumab on muscle structure post-IS and the role of calcium balance in muscle strength, while validating their synergistic effect.
methodsThis study investigates the effects of adalimumab and GV-58 on muscle structure and function in male middle cerebral artery occlusion (MCAO) rat models using behavioural, imaging, pathological and WB experiments. In vitro mechanisms are explored with L6 and primary muscle cells.
resultsThe results of the present study showed a significant decrease in motor function in IS-induced sarcopenia (ISS) rats, as evidenced by shortened length (-47.56%, p < 0.001), reduced weight (-43.79%, p < 0.001) and reduced cross-sectional area of myofibroblasts (-38.58%, p < 0.001) in the soleus muscle as compared to the sham group. Inflammatory factors such as IL-1β, IL-6, TNF-α and reactive oxygen species (ROS) levels were significantly elevated in the muscles of ISS rats (3.10-fold, 3.78-fold, 2.29-fold, 2.80-fold, p < 0.001). Molecular mechanism studies showed that TNF-α, MAFbx and MuRF1 protein expression was down-regulated, and IL-10 and MyoD1 expression was up-regulated in muscle tissues of ISS rats. RNA-seq implicated the Ca
conclusionsThe combination of adalimumab and GV-58 effectively restores muscle function after stroke by inhibiting inflammation and improving calcium channel dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.